News
May 2011:
Signum’s scientists have published a review on the drug ability of PP2A for Alzheimer’s disease, further supporting the value and potential of our approaches. This review brings together a wealth of data demonstrating the safe and efficacious targeting of this critical enzyme whose activity is compromised in disease.
Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer’s disease. Future Med Chem. 2011 May; 3(7):821-33.
May 2011
SciBX has published an article on Signum’s work modulating PP2A demethylation in a model of Parkinson’s disease. This article, from a key journal in the Nature Publishing Group, highlights the translational impact of Signum’s work and findings.
Extracting PD therapy from coffee. Science-Business eXchange 4, doi:10.1038/scibx.2011.590
May 2011:
Signum’s work on efficacy of inhibiting PP2A demethylation in a model of Parkinson’s disease has been published in the prestigious Journal of Neuroscience. This work for the first time links PP2A to alpha-synuclein dephosphorylation in a methylation dependent manner and demonstrates the efficacy of pharmacological modulation of this mechanism for disease modification in an alpha-synuclein transgenic model. The manuscript is available online at http://www.jneurosci.org/content/31/19/6963.full
Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model. The Journal of Neuroscience, 11 May 2011, 31(19):6963-6971.
March 2011
At the 10th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2011) in Barcelona, Spain, Signum presented two posters on its technology:
Braithwaite et al. Protein Phosphatase 2A Modulation Is Disease Modifying in Transgenic and Pharmacological Models of Parkinson’s Disease
Stock et al. Modulation of PP2A Activity by a Component of Coffee is Beneficial in Models of Alzheimer’s Disease
January 2011
Signum Biosciences, Inc. spins out Argyle Therapeutics, Inc. to develop Signum’s anti-inflammatory dermatology assets. Signum has assigned to Argyle all of the relevant intellectual property related to dermatological diseases. http://argyletherapeutics.com/about.html
